Vaccine AV0407
We will be developing a separate and distinct formulation for the vaccine for its use in neuroinflammation. The rationale is that chronic neuroinflammatory diseases may require different levels of immunity to be effective. To accomplish that we will develop a formulation utilizing a different adjuvant.
AV0407
| Compound | Indication | Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
AV0407 |
Discovery Phase complete
|
Pre-Clinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|